Targeting XRCC1 deficiency in breast cancer for personalized therapy

Cancer Research

Volumn 73, Issue 5, 2013, Pages 1621-1634

  Sultana, Rebeka ^a   Abdel Fatah, Tarek ^d   Abbotts, Rachel ^b   Hawkes, Claire ^b   Albarakati, Nada ^a   Seedhouse, Claire ^c   Ball, Graham ^e   Chan, Stephen ^d   Rakha, Emad A ^b   Ellis, Ian O ^b   Madhusudan, Srinivasan ^a,d  

^a Academic Unit of Oncology   (United Kingdom)

^b Division of Pathology   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 8 (4 DIBENZOTHIENYL) 2 (4 MORPHOLINYL) 4H 1 BENZOPYRAN 4 ONE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; METHOTREXATE; NU 7441; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ADJUVANT THERAPY; ANIMAL CELL; APOPTOSIS; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER MORTALITY; CANCER THERAPY; CHEMOSENSITIVITY; COHORT ANALYSIS; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; G2 PHASE CELL CYCLE CHECKPOINT; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LETHALITY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; TRIPLE NEGATIVE BREAST CANCER; VALIDATION STUDY;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CRICETINAE; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS;

EID: 84874818045     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2929     Document Type: Article

References (43)

1. Sieber OM, Heinimann K, Tomlinson IP. Genomic instability-the engine of tumorigenesis? Nat Rev Cancer 2003;3:701-8.
2. Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: Clinical implications. Cancer Res 2008;68:3551-7.
3. Ladiges WC. Mouse models ofXRCC1DNArepair polymorphisms and cancer. Oncogene 2006;25:1612-9.
4. Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH. XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res 2008;18:48-63.
5. Zhang R, Niu Y, Zhou Y. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol Lett 2010;192:108-14.
6. Wilson DM III, Kim D, Berquist BR, Sigurdson AJ. Variation in base excision repair capacity. Mutat Res 2011;711:100-12.
7. Chen B, Zhou Y, Yang P,WuXT. Polymorphisms of XRCC1 and gastric cancer susceptibility: A meta-analysis. Mol Biol Rep 2012;39:1305-13.
8. Yuan T, Deng S, Chen M, Chen W, Lu W, Huang H, et al. Association of DNA repair gene XRCC1 and XPD polymorphisms with genetic susceptibility to gastric cancer in a Chinese population. Cancer Epidemiol 2011;35:170-4.
9. Corso G, Marrelli D, Pedrazzani C, Machado JC, Mancini S, Seruca R, et al. Gastric cardia carcinoma is associated with the promoter-77T>C gene polymorphism of X-ray cross-complementing group 1 (XRCC1). J Gastrointest Surg 2009;13:2233-8.
10. Chang-Claude J, Popanda O, Tan XL, Kropp S, Helmbold I, Von Fournier D, et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 2005;11: 4802-9.
11. Zhou L, Xia J, Li H, Dai J, Hu Y. Association of XRCC1 variants with acute skin reaction after radiotherapy in breast cancer patients. Cancer Biother Radiopharm 2010;25:681-5.
12. Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 2006;24:5645-51.
13. Gossage L, Madhusudan S. Cancer pharmacogenomics: Role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 2007;11:361-80.
14. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009; 65:230-6.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
16. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992;20:479-89.
17. Galea MH, Blamey RW, Elston CE, Ellis IO. The NottinghamPrognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22: 207-19.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
19. Abdel-Fatah TM, Powe DG, Ball G, Lopez-Garcia MA, Habashy HO, Green AR, et al. Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J Pathol 2010; 222:388-99.
20. Abdel-Fatah TM, Powe DG, Agboola J, Adamowicz-Brice M, Blamey RW, Lopez-Garcia MA, et al. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 2010;220:419-34.
21. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006;12:2468-75.
22. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, et al. Triple negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111:27-44.
23. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Aldred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25: 118-45.
24. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
25. Zdzienicka MZ, van der Schans GP, Natarajan AT, Thompson LH, Neuteboom I, Simons JW. A Chinese hamster ovary cell mutant(EM-C11) with sensitivity to simple alkylating agents and a very high level of sister chromatid exchanges. Mutagenesis 1992;7:265-9.
26. Berquist BR, Singh DK, Fan J, Kim D, Gillenwater E, Kulkarni A, et al. Functional capacity of XRCC1 protein variants identified in DNArepairdeficient Chinese hamster ovary cell lines and the human population. Nucleic Acids Res 2010;38:5023-35.
27. Fan J, Wilson PF, Wong HK, Urbin SS, Thompson LH, Wilson DM III. XRCC1 down-regulation in human cells leads to DNA-damaging agent hypersensitivity, elevated sister chromatid exchange, and reduced survival of BRCA2 mutant cells. Environ Mol Mutagen 2007;48: 491-500.
28. Sultana R, McNeill DR, Abbotts R, Mohammed MZ, Zdzienicka MZ, Qutob H, et al. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer 2012;131:2433-44.
29. Derheimer FA, Kastan MB. Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett 2010;584:3675-81.
30. Hill R, Lee PW. The DNA-dependent protein kinase (DNA-PK): More than just a case of making ends meet? Cell Cycle 2010;9:3460-9.
31. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004; 64:9152-9.
32. Leahy JJ, Golding BT, Griffin RJ, Hardcastle IR, Richardson C, Rigoreau L, et al. Identification of a highly potent and selective DNAdependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett 2004;14:6083-7.
33. Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004;103:4659-65.
34. Beckman RA, Loeb LA. Efficiency of carcinogenesis with and without a mutator mutation. Proc Natl Acad Sci U S A 2006;103:14140-5.
35. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19.
36. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997;99:1478-83.
37. Toulany M, Dittmann K, Fehrenbacher B, Schaller M, Baumann M, Rodemann HP. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. DNA Repair (Amst) 2008;7:1746-56.
38. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012;481:287-94.
39. Neal JA, Dang V, Douglas P, Wold MS, Lees-Miller SP, Meek K. Inhibition of homologous recombination by DNA-dependent protein kinase requires kinase activity, is titratable, and is modulated by autophosphorylation. Mol Cell Biol 2011;31:1719-33.
40. Chou WC, Wang HC, Wong FH, Ding SL,WuPE, Shieh SY, et al. Chk2-dependent phosphorylation of XRCC1 in the DNA damage response promotes base excision repair. EMBO J 2008;27:3140-50.
41. Levy N, Martz A, Bresson A, Spenlehauer C, de Murcia G, Menissier-de Murcia J. XRCC1 is phosphorylated by DNA-dependent protein kinase in response to DNA damage. Nucleic Acids Res 2006;34:32-41.
42. DiBiase SJ, Zeng ZC, Chen R, Hyslop T, Curran WJ Jr, Iliakis G. DNAdependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res 2000;60:1245-53.
43. Wang H, Perrault AR, Takeda Y, Qin W, Wang H, Iliakis G. Biochemical evidence for Ku-independent backup pathways of NHEJ. Nucleic Acids Res 2003;31:5377-88.